- Home
- SLMT vs SLS Comparison
SLMT vs SLS Comparison
Compare SLMT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMT | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.4M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLMT | SLS |
|---|---|---|
| Price | $2.06 | $4.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.6M | ★ 12.2M |
| Earning Date | 02-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,132,646.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 70.92 | N/A |
| 52 Week Low | $1.71 | $0.85 |
| 52 Week High | $52.95 | $5.18 |
Technical Indicators
Market Signals| Indicator | SLMT | SLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 68.28 |
| Support Level | N/A | $3.62 |
| Resistance Level | N/A | $5.18 |
| Average True Range (ATR) | 0.00 | 0.51 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 0.00 | 62.78 |
Price Performance
Historical ComparisonAbout SLMT Brera Holdings PLC Class B Ordinary Shares
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.